[
  {
    "letter_name": "13-vapor-co-llc-619153-11092021",
    "violated_terms": [
      "The e-liquid product 13 Vapor Ripe Strawberry 3mg 20mL is being sold without a marketing authorization order, which is required for new tobacco products under section 910(c)(1)(A)(i) of the FD&C Act [21 U.S.C. § 387j(c)(1)(A)(i)].",
      "The product is considered adulterated under section 902(6)(A) of the FD&C Act because it lacks the necessary marketing authorization [21 U.S.C. § 387b(6)(A)].",
      "The product is misbranded under section 903(a)(6) of the FD&C Act due to the absence of required notice or information as mandated by section 905(j) [21 U.S.C. § 387c(a)(6)].",
      "The failure to provide required reports under section 905(j) of the FD&C Act constitutes a prohibited act under section 301(p) [21 U.S.C. § 331(p)]."
    ],
    "recommendations": [
      "Submit a written response to the FDA within 15 working days detailing corrective actions taken to address the violations and bring products into compliance.",
      "Discontinue the sale and distribution of the violative tobacco products immediately.",
      "Provide a comprehensive plan for maintaining compliance with the FD&C Act, including the dates on which the violative sales were discontinued."
    ]
  },
  {
    "letter_name": "1-party-time-609781-09012020",
    "violated_terms": [
      "The product BetterFly is an unapproved new drug sold in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) [21 U.S.C. § 355(a)].",
      "BetterFly is a misbranded drug under section 502 of the FD&C Act [21 U.S.C. § 352].",
      "The introduction or delivery for introduction of this product into interstate commerce is prohibited under sections 301(a) and (d) of the FD&C Act [21 U.S.C. § 331(a) and (d)].",
      "The claims made on the website regarding BetterFly's ability to mitigate, prevent, treat, diagnose, or cure COVID-19 mislead consumers about the product's safety and effectiveness."
    ],
    "recommendations": [
      "Cease the sale of BetterFly and any other unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19 immediately.",
      "Review and correct all promotional materials, including websites and product labels, to ensure compliance with the FD&C Act and avoid misleading representations.",
      "Within 48 hours, send an email to COVID-19-Task-Force-CDER@fda.hhs.gov detailing the specific steps taken to correct the violations and prevent recurrence.",
      "If unable to complete corrective actions within 48 hours, provide a reason for the delay and a timeline for completion.",
      "Cease making any claims regarding the prevention or treatment of COVID-19 that are not supported by competent and reliable scientific evidence, as required under the FTC Act."
    ]
  },
  {
    "letter_name": "11-11-11-brands-627690-11162022",
    "violated_terms": [
      "Your Mood33 Hemp Infused Herbal Tea products are adulterated under section 402(a)(2)(C)(i) of the Federal Food, Drug, and Cosmetic Act (the FD&C Act) [21 U.S.C. 342(a)(2)(C)(i)], because they bear or contain an unsafe food additive.",
      "It is a prohibited act to introduce your Mood33 Hemp Infused Herbal Tea products into interstate commerce under sections 301(ll) and 301(a) of the FD&C Act [21 U.S.C. 331(ll) and 331(a)].",
      "CBD is deemed a food additive under section 201(s) of the FD&C Act [21 U.S.C. 321(s)] and requires premarket approval based on safety data, which has not been provided.",
      "The introduction of an adulterated food into interstate commerce is prohibited under section 301(a) of the FD&C Act [21 U.S.C. 331(a)].",
      "The prohibition under section 301(ll) of the FD&C Act [21 U.S.C. 331(ll)] applies to CBD, as it is an active ingredient in an approved drug and substantial clinical investigations have been made public."
    ],
    "recommendations": [
      "Notify FDA in writing within fifteen working days of receipt of this letter regarding the specific steps taken to correct these violations.",
      "Include an explanation of each step being taken to prevent the recurrence of violations, along with copies of related documentation.",
      "If corrective action cannot be completed within fifteen working days, state the reason for the delay and the timeframe for completion.",
      "Ensure that all product labeling accurately reflects the ingredients, including the presence of CBD, to prevent consumer confusion."
    ]
  },
  {
    "letter_name": "1-stop-supply-corp-dba-1-stop-vapor-supply-685573-06122024",
    "violated_terms": [
      "You offer for sale or distribution ENDS and e-liquid products that lack a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act [21 U.S.C. § 387j(c)(1)(A)(i)].",
      "The products Cereal Trip - Bad Drip Lab 60mL – 3mg, Don’t Care Bear by Bad Drip Labs 60ml – 3mg, and Funky Republic Ti7000 Smart Disposable - Blue Red Mint are considered new tobacco products because they were not commercially marketed in the United States as of February 15, 2007, and lack the required marketing authorization [21 U.S.C. § 387j(a)].",
      "These products are adulterated under section 902(6)(A) of the FD&C Act [21 U.S.C. § 387b(6)(A)] because they do not have FDA marketing authorization orders in effect.",
      "The products are misbranded under section 903(a)(6) of the FD&C Act [21 U.S.C. § 387c(a)(6)] due to the lack of required notice or information as mandated by section 905(j) of the FD&C Act [21 U.S.C. § 387e(j)]."
    ],
    "recommendations": [
      "Discontinue the sale and distribution of the listed products (Cereal Trip - Bad Drip Lab 60mL – 3mg, Don’t Care Bear by Bad Drip Labs 60ml – 3mg, and Funky Republic Ti7000 Smart Disposable - Blue Red Mint) immediately to comply with the FD&C Act.",
      "Submit a written response to the FDA within 15 working days detailing the actions taken to address the violations, including the dates on which the violative sales were discontinued.",
      "Implement a plan to ensure that all tobacco products sold or distributed comply with the FD&C Act and its implementing regulations, including maintaining proper marketing authorization for any new tobacco products."
    ]
  },
  {
    "letter_name": "1-stop-chicken-health-shop-689150-07292024",
    "violated_terms": [
      "Marketing of unapproved new animal drugs violates section 301(a) of the FD&C Act [21 U.S.C. § 331(a)] due to introduction of unapproved drugs into interstate commerce.",
      "Products are considered drugs under section 201(g)(1)(B) of the FD&C Act [21 U.S.C. § 321(g)(1)(B)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in animals.",
      "Products are misbranded under section 502(o) of the FD&C Act [21 U.S.C. § 352(o)] as they have not been drug listed with the FDA.",
      "Products are new animal drugs under section 201(v) of the FD&C Act [21 U.S.C. § 321(v)] because they are not generally recognized as safe and effective for their intended use.",
      "The products are unsafe under section 512(a) of the FD&C Act [21 U.S.C. § 360b(a)] and adulterated under section 501(a)(5) of the FD&C Act [21 U.S.C. § 351(a)(5)] due to lack of FDA approval."
    ],
    "recommendations": [
      "Cease the marketing and distribution of the unapproved new animal drugs immediately.",
      "Submit a written response within fifteen (15) working days detailing the specific steps taken to address the violations.",
      "Provide an explanation of each step being taken to prevent recurrence of violations, along with copies of related documentation.",
      "If corrective action cannot be completed within the specified timeframe, provide reasons for the delay and a timeline for completion.",
      "If the firm believes the products are not in violation of the FD&C Act, include reasoning and supporting information for FDA's consideration."
    ]
  }
]